- P3 Health Partners Inc PIII provided a preliminary sales forecast for 2023 of $1.20 billion to $1.25 billioncompared to the consensus of $1.30 billion.
- The Company expects an Adjusted EBITDA loss of $(40) million to $(60) million. It expects its Adjusted EBITDA to be positive in 2024.
- For full year 2022, P3 reiterated revenue guidance of $1.025 billion to $1.075 billion, up 61% to 69% Y/Y, versus consensus of $1.04 billion.
- These expectations put the total number of at-risk members in the range of 115,000 to 120,000 in 2023, an increase of approximately 15% over 2022 member expectations.
- Similarly, management expects membership to end north of 100,000 lives in 2022, up 35% year over year.
- William Blair According to analysts, P3 Health Partners is a solid growth stock in healthcare, and its primary care model is set for significant changes in the years to come.
- William Blair writes that this is a strong preliminary outlook for the company given the recent challenges the company has faced in 2022.
- P3 Health Partner’s organic growth prospects are among the strongest in William Blair’s healthcare coverage universe. It is repeating outperformance rating for the stock.
- Price promotion: PIII shares closed up 4.11% at $1.52 in after-hours trading on Wednesday.
- Photo via company
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
[ad_2]
Source story
